Market closed · Next open: Tuesday 9:30 AM ET
Last update: Jul 20, 2026, 5:23 PM ET
Medline Inc.
$38.88 2.29% today
Market Closed

Why Medline Inc. (MDLN) stock moved

Updated Jul 21, 2026

Medline Inc. (MDLN) shares fell 2.3% to $38.88 as of July 21, 2026, a modest decline from the prior close of $39.79. BestStocks flagged the session as a major change for MDLN. Below, we break down what changed for MDLN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MDLN fell 2.3% to $38.88

MDLN fell 2.3% in its latest session, moving from $39.79 to $38.88.

RiskWeak confidence
Rel. volume
0.8×
Below Avg
Vs peers
No comparable peers
Market cap
$32.9B
NASDAQ Global Select
Analyst target
$52
+32.8% vs price
Price chart
Jun 22 – Jul 21
VVVVVVF$35$39$43Jun 22Jun 29Jul 7Jul 14Jul 21
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Medline Inc. investors

For Medline Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Medline Inc. (MDLN) moved +4.23% from $39.44 to $41.11 on 2026-07-16; Positive price momentum. Weighing against that: Negative session, down 2.3%; Medline Inc. (MDLN) moved -3.21% from $41.11 to $39.79 on 2026-07-17. Wall Street's consensus price target sits at $51.63, implying +32.8% upside from $38.88. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 15 days out, the next report is the most likely near-term test of the move.

MDLN price reaction

MDLN last traded at $38.88, down $0.91 (-2.29%) from the previous close of $39.79. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $34.71 and $43.19, and it currently sits about 49% of the way up that band.

Bullish and bearish analyst opinions on Medline Inc. (MDLN)

The consensus analyst price target on Medline Inc. (MDLN) is $51.63, 32.8% above the recent $38.88. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDLN line up.

The bullish case

  • Wall Street's consensus price target of $51.63 implies +32.8% upside from $38.88.
  • The Street's most bullish target is $60.00 (+54.3%).
  • Medline Inc. (MDLN) moved +4.23% from $39.44 to $41.11 on 2026-07-16.
  • Positive price momentum.

The bearish case

  • Negative session, down 2.3%.
  • Medline Inc. (MDLN) moved -3.21% from $41.11 to $39.79 on 2026-07-17.
  • MDLN moved -6.30% from $43.01 to $40.30 on 2026-07-08.
Bull vs bear balanceBearish Shift
BearishNeutralBullish

Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $52+32.8%
= 7 maintains
Baird maintained Outperform · 2026-06-03
SEC filings watch
8-K2026-07-09
Material event — review for impact
high
8-K2026-06-12
Material event — review for impact
high
8-K2026-06-02
Material event — review for impact
high
S-12026-05-20
Securities registration
high
Peer context
MDLN-2.3%

Previous notable changes for MDLN

Risk2026-07-17-3.2%
Medline Inc. (MDLN) moved -3.21% from $41.11 to $39.79 on 2026-07-17. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume traded near its 5-day average, indicating the move occurred without unusual trading intensity.
Activity2026-07-16+4.2%
Medline Inc. (MDLN) moved +4.23% from $39.44 to $41.11 on 2026-07-16. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.4x the 5-day average, suggesting modest institutional participation.
Risk2026-07-14-4.7%
Medline Inc. (MDLN) moved -4.73% from $40.58 to $38.66 on 2026-07-14. We checked news, earnings, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume was 1.5x the 5-day average, indicating modestly elevated trading activity accompanying the decline.
Filings2026-07-09+1.4%
Medline Inc. (MDLN) filed a new 8-K on July 9, 2026.
Upcoming catalysts & outlook
Next earnings
2026-08-05 (est.)
in 15 days
Thesis shift
Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about MDLN

Why did Medline Inc. (MDLN) stock move?

MDLN fell 2.3% to $38.88. No single company-specific catalyst was confirmed during the move window, and it looks technical.

How much did MDLN stock fall?

MDLN lost 2.29% ($0.91) versus the prior close of $39.79, last trading at $38.88 on 0.8× average volume.

When is Medline Inc.'s next earnings date?

MDLN's next earnings report is estimated for 2026-08-05 — about 15 days away.

What is the analyst price target for MDLN?

The consensus analyst price target for MDLN is $51.63, about 32.8% above the current $38.88. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 0 downgrades.

How BestStocks tracks MDLN

This page is generated automatically by BestStocks' change-detection system after its price and volume cleared MDLN-specific materiality thresholds, triggering an evidence check. It draws on 9 tracked change events for MDLN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataSEC EDGAR filingsFMP earnings & estimatesAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.